Roquette expands plant-based excipient portfolio with Crest Cellulose acquisition
.png)
Crest Cellulose, an Indian excipient manufacturer, has been acquired by plant-based pharmaceutical excipient provider Roquette in a bid to increase the latter’s presence in the Asia Pacific region.
French provider of plant-based ingredients and pharmaceutical/nutraceutical excipients Roquette has announced their complete acquisition of Indian excipient manufacturer Crest Cellulose, expanding their capacity to meet global demand for plant-based excipients.
India’s pharmaceutical industry is one of the largest global providers of generic medicines at a time when the production of generics in the Asia Pacific region is increasing in general. The acquisition of Crest Cellulose is hoped to establish a reinforced presence for Roquette in India and Asia, while also providing a global network of pharmaceutical research, development, and innovation facilities.
Crest Cellulose is set to be smoothly integrated into Roquette’s existing rigorous quality standards, meeting all major international regulatory requirements for excipients produced at the facility. Such plant-based excipients include MICROCEL, a microcrystalline cellulose, and LYCATAB CT, a partially pregelatinized starch.
VP Roquette Pharma Solutions Paul Smaltz commented on the acquisition: “At Roquette, we believe true innovation can only be achieved in an environment where ingredient safety is completely assured... There’s no room for compromise or shortcuts when tackling the world’s greatest health challenges. The team at Crest Cellulose share our conviction that quality is king, always striving to optimize processes and redefine what’s possible in drug delivery. As a global leader in health and nutrition, we’re excited to harness our newly expanded capabilities to support our network of customers and partners in India, Asia, and the rest of the world.
The acquisition will also focus on protecting the health of the planet and sustainable practices, a core pillar of Roquette’s ethos in bringing about healthier futures. Crest Cellulose will become the latest recipient of the Greentech ‘Environmental Protection’ award, recognising the environmental efforts of companies respecting the planet and its natural resources. Smaltz added: “Adding Crest Cellulose to the Roquette family gives us an opportunity to expand the reach of our sustainable development initiatives underpinned by four key pillars – innovating, sourcing, biorefining, acting – to build a healthier tomorrow. For Crest Cellulose and its customers, this means sustainable development will become central to every operation – ensuring we deliver top quality solutions that champion people, the planet, and prosperity. Supporting our commitment to reducing greenhouse gas emissions by 25% between 2021 and 2030, plans are in motion to install an additional 0.5 megawatt solar panel to the 10 kilowatts already in place at the site. This investment is designed to provide renewable energy for decades to come.”
Source: Roquette Complete Acquisition of Crest Cellulose - Corporate Pharma| Roquette
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance